STOCK TITAN

Cellebrite Completes Acquisition of Corellium, Extending the Industry’s Most Advanced AI-Powered Digital Investigation Platform

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

Cellebrite (NASDAQ: CLBT) completed the acquisition of Corellium on Dec 2, 2025, combining Corellium’s Arm-based virtualization with Cellebrite’s AI-powered digital investigation platform.

The transaction value was $170 million (including $150 million cash at closing, $20 million converted to equity, and up to $30 million in performance-based cash over two years). Corellium CTO Chris Wade joined Cellebrite as CTO. CFIUS permitted closing under a negotiated national security agreement pending formal agency execution. Cellebrite said one month of Corellium results will not materially affect 2025 outlook.

Loading...
Loading translation...

Positive

  • $170M acquisition expands virtualization capabilities
  • Adds Arm-based virtualization to Cellebrite’s AI platform
  • Corellium CTO Chris Wade joined as chief technology officer
  • Expected to broaden defense, intelligence and enterprise use cases

Negative

  • $150M paid in cash at closing reduces liquidity
  • Up to $30M contingent cash earnout over two years
  • Closing required a CFIUS national security agreement (conditional)

Key Figures

Enterprise value $170 million Corellium acquisition consideration
Cash at closing $150 million Portion of Corellium purchase price paid in cash
Equity consideration $20 million Corellium value converted to Cellebrite equity
Earnout potential $30 million Additional cash based on performance milestones over two years
Earnout period 2 years Performance milestone measurement window for Corellium securityholders
Conference date December 2, 2024 UBS Global Technology and AI Conference participation
Presentation time 4:15 p.m. MT Scheduled time for UBS conference fireside chat

Market Reality Check

$5.25 Last Close
Volume Volume 1718685 versus 20-day average of 1437041 shows elevated trading interest ahead of this news. normal
Technical Price 19.06 is trading above the 200-day MA at 17.23, indicating a pre-existing upward trend.

Peers on Argus

Peers in Software - Infrastructure showed mixed moves, with names like AVPT and QLYS up while BOX and PAY were down or flat, suggesting CLBT’s move around 0.6% was more stock-specific than sector-driven.

Historical Context

Date Event Sentiment Move Catalyst
Dec 02 Strategic acquisition Positive +3.9% Closed $170M Corellium deal, expanding AI-powered digital investigation platform.
Nov 12 Earnings results Positive +1.7% Q3 2025 beat with strong ARR, revenue growth and reiterated full-year guidance.
Oct 30 Leadership change Neutral -1.3% Appointed new General Counsel and Chief Compliance Officer to oversee legal matters.
Oct 28 Conference announcement Neutral -0.1% Announced 2026 C2C User Summit featuring advocacy and showcasing Corellium tech.
Oct 17 Earnings scheduling Neutral +0.4% Set date and details for Q3 2025 earnings release and investor call.
Pattern Detected

Recent news events, including earnings and this Corellium acquisition, have generally coincided with positive share reactions, while neutral corporate updates saw limited moves.

Recent Company History

Over recent months, Cellebrite reported strong Q3 2025 metrics, including revenue of $126.0M and ARR of $439.8M, and reiterated full-year guidance excluding Corellium. Corporate updates covered leadership changes and conference participation. On Dec 2, 2025, it completed the $170M Corellium acquisition, integrating Arm-based virtualization into its AI-powered investigative platform. That deal followed earlier messaging that Corellium was not included in 2025 guidance, framing this announcement as a strategic, rather than near-term financial, catalyst.

Market Pulse Summary

This announcement details Cellebrite’s completion of the $170M Corellium acquisition, adding Arm-based virtualization to its AI-powered investigation platform. The structure includes $150M in cash, $20M in equity, and up to $30M in earnouts over two years, with management indicating the one-month 2025 impact is not material. Investors may focus on how the combined offerings resonate with defense, intelligence and enterprise customers and monitor future disclosures on revenue contribution and integration progress.

Key Terms

virtualization technical
"Corellium’s leading virtualization technology to the Cellebrite platform delivers..."
Virtualization creates software versions of physical computing resources—such as running multiple independent “virtual” computers, storage pools, or networks inside a single physical machine—allowing firms to do more with less hardware and to scale services quickly. It matters to investors because it lowers capital and operating costs, speeds product deployment, and supports cloud and security strategies that can improve efficiency and profitability; think of turning one big building into many flexible apartments.
Arm-based virtualization software technical
"Corellium, a leader in Arm-based virtualization software."
Arm-based virtualization software creates isolated, virtual computers or application environments that run on processors built with the ARM architecture, letting multiple workloads share the same physical chip while staying separated—think of running several apps in separate rooms of a house. Investors care because ARM processors are prized for energy efficiency and are expanding beyond phones into servers and edge devices; effective virtualization on ARM enables lower cloud costs, easier software rollout across devices and new market opportunities that can drive hardware and software revenue.
enterprise value financial
"Cellebrite acquired Corellium for an enterprise value of $170 million..."
Enterprise value is the total worth of a company, reflecting what it would cost to buy the entire business. It includes the company's market value plus any debts, minus its cash holdings, offering a comprehensive picture of its true value. Investors use it to compare companies regardless of their capital structures, helping them assess how much they would need to pay to acquire the business.
CFIUS regulatory
"The Committee on Foreign Investment in the United States (CFIUS) has permitted..."
The Committee on Foreign Investment in the United States (CFIUS) is a U.S. government panel that reviews transactions where foreign parties seek control or substantial influence over U.S. businesses to check for national security risks. Investors should care because CFIUS can block, force changes to, or unwind deals much like a safety inspector stopping or altering a construction project, and that can change deal value, timing, or whether a transaction can close at all.
national security agreement regulatory
"on the basis of a national security agreement negotiated with relevant..."
A national security agreement is a legally binding pact between a government and a business that sets rules to protect sensitive technology, data, or infrastructure from risks to a country’s safety. Think of it as a safety checklist or locked-door arrangement that can limit how a company operates, who it can partner with, or what it can export. Investors watch these agreements because they can affect a deal’s approval, add compliance costs, or restrict future growth and market access.
pentesting technical
"transformed our mobile security testing by tripling our pentesting coverage..."
Penetration testing, often called pentesting, is when security professionals simulate real cyberattacks on a company's systems, networks or applications to identify vulnerabilities before malicious actors can exploit them. For investors, pentesting matters because it helps lower the chance of costly data breaches, regulatory penalties and reputational harm — like a home inspection that uncovers hidden problems before you buy — and signals proactive risk management.
IoT technical
"validate next-generation mobile applications, as well as IoT and automotive systems."
The Internet of Things (IoT) describes a network of everyday devices—such as appliances, vehicles, and equipment—that are connected to the internet and can share data automatically. For investors, IoT represents a growing trend that can drive efficiency and innovation across many industries, potentially creating new opportunities for growth and value. Its expansion influences how companies operate and compete in a digitally connected world.

AI-generated analysis. Not financial advice.

The addition of Corellium’s leading virtualization technology to the Cellebrite platform delivers unmatched capabilities that transcend digital forensics, investigations, analytics and intelligence

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced it has substantially expanded its capabilities through the acquisition of Corellium, a leader in Arm-based virtualization software. The addition of Corellium's technology and world-class technical talent further strengthens Cellebrite's market and technology leadership.

This combination creates the industry's most complete digital investigation portfolio spanning physical device access, virtual device testing and real-time intelligence. The technology enables investigators, security researchers and intelligence professionals to work without physical device constraints while dramatically accelerating time to evidence and threat detection.

The acquisition significantly expands the value of Cellebrite's AI-powered capabilities for a wide variety of customers. For example, defense and intelligence customers gain advanced virtualization for secure mobile application development, operational testing and accelerated mobile vulnerability discovery. Enterprise development and security operations teams can more efficiently and effectively design and validate next-generation mobile applications, as well as IoT and automotive systems.

“We are thrilled to officially welcome the Corellium team to the Cellebrite family,” said Thomas E. Hogan, Cellebrite’s chief executive officer. “Since announcing our agreement to acquire Corellium several months ago, we have been overwhelmed by interest in Corellium’s solutions. We are eager to unleash the power of this combination. This acquisition is an important step forward for Cellebrite as we continue to raise the bar for how technology can better protect citizens, communities, businesses and nations.”

With the closing of this transaction, Chris Wade, Corellium’s co-founder and chief technology officer, has joined the Cellebrite leadership team as chief technology officer. “Cellebrite was the ideal home for Corellium’s technology and people,” said Wade. “The breadth and depth of the technical talent and resources across Cellebrite are impressive and inspiring. I look forward to collaborating with my colleagues to accelerate customer-focused innovation and further advance the Company’s mission.”

The Committee on Foreign Investment in the United States (CFIUS) has permitted the acquisition to close on the basis of a national security agreement negotiated with relevant government agencies and executed by Cellebrite and Corellium pending formal clearance by CFIUS and execution of that agreement by such agencies.

Customers on the Acquisition

“This combination addresses the full spectrum of our mobile security and forensics requirements in a way no other solution can, giving us an unparalleled unified platform for both advanced security research and critical investigative operations.”
- Principal security researcher, European intelligence agency

“Corellium Viper has already transformed our mobile security testing by tripling our pentesting coverage while cutting costs by over 60%, and the combination with Cellebrite's platform creates an unmatched capability for protecting our mobile infrastructure at scale.”
-Head of mobile application security, Fortune 100 telecommunications provider

Financial Considerations

Cellebrite acquired Corellium for an enterprise value of $170 million, of which $150 million was paid in cash at closing, with $20 million converted to equity. Corellium securityholders will receive up to an additional $30 million in cash based on the achievement of certain performance milestones over the next two years.

Cellebrite’s fourth-quarter and full-year 2025 expectations, which were provided most recently on November 12, 2025, did not include any impact from the Corellium acquisition. Please note that Cellebrite is not updating its fourth-quarter and full-year 2025 outlook at this time as the fourth-quarter impact from one month of Corellium’s revenue and costs is not expected to be material.

Cellebrite to Participate at the UBS Global Technology and AI Conference

Cellebrite also announced today that it will participate in the upcoming UBS Global Technology and AI Conference. Relevant details include:

Date:December 2, 2024
Conference:UBS Global Technology and AI Conference
Presentation Time:4:15 p.m. MT
FormatFireside Chat
Event URL:https://investors.cellebrite.com/events/event-details/ubs-global-technology-and-ai-conference-0
Webcast URL:https://event.webcasts.com/starthere.jsp?ei=1742777&tp_key=ef086d12e1&tp_special=8
Cellebrite Executives:
Thomas Hogan, chief executive officer
David Barter, chief financial officer
Andrew Kramer, vice president, investor relations
  

References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite’s AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate more than 1.5 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite’s technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com, https://investors.cellebrite.com/investors and find us on social media @Cellebrite.

Media 
Victor Cooper
Sr. Director of Corporate Communications and Content Strategy
victor.cooper@cellebrite.com
+1 404.804.5910

Investor Relations 
Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760 

Caution Regarding Forward Looking Statements
This document includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, the Company’s expectations for the fourth quarter of 2025 and for fiscal year 2025, which was previously disclosed on November 12, 2025; certain statements such as the anticipated contribution of Corellium’s business to Cellebrite’s fourth-quarter and 2025 annual recurring revenue, revenue and costs; the successful execution of a national security agreement negotiated with relevant government agencies and executed by Cellebrite and Corellium, and formal clearance by CFIUS; and any commentary about future performance, strategies, prospects, and other aspects of Cellebrite’s business. These forward-looking statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s digital investigation solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; Cellebrite’s dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite’s dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.


FAQ

What did Cellebrite announce about acquiring Corellium on Dec 2, 2025 (CLBT)?

Cellebrite announced it completed the acquisition of Corellium, adding Arm-based virtualization to its AI investigation platform for an enterprise value of $170M.

How much did Cellebrite pay in cash for Corellium and what are the deal terms for CLBT?

Cellebrite paid $150M in cash at closing, converted $20M to equity, with up to $30M additional cash based on milestones over two years.

Will the Corellium acquisition change Cellebrite’s 2025 guidance (CLBT)?

Cellebrite said it is not updating its Q4 or full-year 2025 outlook because one month of Corellium revenue and costs is not expected to be material.

Who from Corellium joined Cellebrite’s leadership after the acquisition of Corellium by CLBT?

Corellium co-founder and CTO Chris Wade joined Cellebrite as chief technology officer.

Did regulators approve the Cellebrite-Corellium deal for CLBT?

CFIUS permitted the acquisition to close under a negotiated national security agreement pending formal execution by relevant agencies.

How will Corellium’s technology affect Cellebrite’s customer use cases (CLBT)?

Corellium’s virtualization is positioned to enable non-physical device testing, faster vulnerability discovery, and expanded mobile, IoT and automotive testing for defense, intelligence and enterprise customers.
Cellebrite Di Ltd

NASDAQ:CLBTW

CLBTW Rankings

CLBTW Latest News

CLBTW Latest SEC Filings

CLBTW Stock Data

203.23M
Software - Infrastructure
Technology
Link
Israel
Petah Tikva